TCR2 Therapeutics Inc. (NASDAQ:TCRR) Expected to Post Earnings of -$0.65 Per Share

Wall Street brokerages expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) to announce earnings of ($0.65) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for TCR2 Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.77). TCR2 Therapeutics posted earnings per share of ($0.56) during the same quarter last year, which would suggest a negative year-over-year growth rate of 16.1%. The firm is expected to issue its next earnings report on Thursday, November 11th.

On average, analysts expect that TCR2 Therapeutics will report full year earnings of ($2.61) per share for the current fiscal year, with EPS estimates ranging from ($2.88) to ($2.12). For the next financial year, analysts anticipate that the firm will report earnings of ($2.89) per share, with EPS estimates ranging from ($3.35) to ($2.60). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow TCR2 Therapeutics.

TCR2 Therapeutics (NASDAQ:TCRR) last released its quarterly earnings results on Thursday, August 5th. The company reported ($0.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04).

Several brokerages have commented on TCRR. BMO Capital Markets dropped their price target on shares of TCR2 Therapeutics from $53.00 to $44.00 and set an “outperform” rating on the stock in a research note on Friday, August 6th. Roth Capital restated a “buy” rating on shares of TCR2 Therapeutics in a research note on Thursday, August 5th. The Goldman Sachs Group began coverage on shares of TCR2 Therapeutics in a research note on Thursday, June 24th. They issued a “buy” rating and a $30.00 price target on the stock. SVB Leerink dropped their price target on shares of TCR2 Therapeutics from $34.00 to $31.00 and set an “outperform” rating on the stock in a research note on Friday, August 6th. Finally, Wedbush lowered shares of TCR2 Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $45.00 to $11.00 in a research note on Friday. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, TCR2 Therapeutics currently has an average rating of “Buy” and an average price target of $35.22.

Shares of TCRR traded down $5.73 on Friday, reaching $9.99. 6,915,518 shares of the company’s stock were exchanged, compared to its average volume of 411,131. The stock has a market capitalization of $381.62 million, a P/E ratio of -4.29 and a beta of 2.10. TCR2 Therapeutics has a 12 month low of $9.94 and a 12 month high of $35.86. The business has a 50 day moving average price of $14.95 and a two-hundred day moving average price of $18.75.

Several hedge funds and other institutional investors have recently bought and sold shares of TCRR. Point72 Hong Kong Ltd acquired a new position in shares of TCR2 Therapeutics during the first quarter valued at approximately $42,000. FORA Capital LLC increased its stake in shares of TCR2 Therapeutics by 255.8% during the second quarter. FORA Capital LLC now owns 2,608 shares of the company’s stock valued at $43,000 after acquiring an additional 1,875 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in TCR2 Therapeutics during the first quarter worth approximately $95,000. E Fund Management Co. Ltd. bought a new stake in TCR2 Therapeutics during the first quarter worth approximately $106,000. Finally, Metropolitan Life Insurance Co NY boosted its holdings in TCR2 Therapeutics by 114,312.5% during the second quarter. Metropolitan Life Insurance Co NY now owns 9,153 shares of the company’s stock worth $150,000 after buying an additional 9,145 shares in the last quarter. Institutional investors and hedge funds own 91.77% of the company’s stock.

TCR2 Therapeutics Company Profile

TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.

Recommended Story: Dual Listing What You Need to Know

Get a free copy of the Zacks research report on TCR2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TCR2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.